LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

34.48 -2.85

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.35

Massimo

35.37

Metriche Chiave

By Trading Economics

Entrata

-3.9M

46M

Vendite

-17M

185M

P/E

Media del settore

13.706

54.533

EPS

0.779

Margine di Profitto

24.663

Dipendenti

268

EBITDA

-10M

56M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+43.61% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

322M

2.1B

Apertura precedente

37.33

Chiusura precedente

34.48

Notizie sul Sentiment di mercato

By Acuity

31%

69%

103 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 mag 2025, 23:25 UTC

Azioni calde

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mag 2025, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mag 2025, 21:29 UTC

Acquisizioni, Fusioni, Takeovers

Millicom to Acquire Telefónica's Operations in Uruguay

21 mag 2025, 21:01 UTC

I principali Market Mover

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mag 2025, 20:51 UTC

Acquisizioni, Fusioni, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21 mag 2025, 23:49 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mag 2025, 23:37 UTC

Discorsi di Mercato

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mag 2025, 23:33 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mag 2025, 23:32 UTC

Acquisizioni, Fusioni, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mag 2025, 23:32 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mag 2025, 23:31 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mag 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mag 2025, 23:30 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mag 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mag 2025, 23:28 UTC

Utili

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mag 2025, 23:27 UTC

Utili

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mag 2025, 23:26 UTC

Utili

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mag 2025, 23:23 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mag 2025, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mag 2025, 23:20 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mag 2025, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mag 2025, 21:42 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mag 2025, 21:14 UTC

Acquisizioni, Fusioni, Takeovers

Millicom to Acquire Telefónica's Ops in Uruguay

21 mag 2025, 21:07 UTC

Notizie principali

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mag 2025, 21:06 UTC

Acquisizioni, Fusioni, Takeovers

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21 mag 2025, 20:59 UTC

Notizie principali

Walmart to Cut 1,500 Jobs -- WSJ

21 mag 2025, 20:52 UTC

Utili

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

43.61% in crescita

Previsioni per 12 mesi

Media 51.57 USD  43.61%

Alto 70 USD

Basso 31 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

6

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Very Strong Bearish Evidence

Sentiment

By Acuity

103 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.